Introduction: The emergence of Plasmodium falciparum resistance to artemisinin combination therapy (ACT) is a worrying development. It calls
Introduction
Commercially available rapid diagnostic tests (RDTs) are numerous in the market. They all fall into three categories: (i) RDTs that detect the Plasmodium falciparum antigen histidine-rich protein 2 (HRP-2), (ii) RDTs that detect lactate dehydrogenase (pLDH) from P. falciparum and (iii) RDTs that detect P. vivax aldolase in human whole blood [1] .
Generally, it is known that P. falciparum (Pf) HRP-2 remains in the bloodstream for an extended time following a successful clearance of the parasite, thus, contributing to false positive results and limiting specificity of the test category that targets PfHRP-2 [2] . In contrast, pLDH is known to be rapidly cleared from the bloodstream and becomes undetectable at about the same time as blood smears become negative after a successful anti-malarial therapy [3, 4] .
In order to monitor the success of an anti-malarial drug therapy, particularly in the presence of fever, pLDH-based tests seem to be more useful since they become negative soon after parasites are cleared from the blood [3] . Thus, pLDH-based tests better discriminate false positive results from treatment failure than HRP-2 tests. SD Bioline malaria AgPf(HRP-2/pLDH) RDT has been reportedly proven to be effective in reducing the rate of false positives caused by the persistence of HRP-2 after a successful drug therapy and guiding accurate prescription and monitoring efficacy of drug therapy in countries like Burkina Faso [4] . However, literature on the performance of the RDT in Kinshasa, DRC is scanty.
The objective of this study was to determine the performance of SD Bioline malaria AgPf(HRP-2/pLDH) 3 band RDT in symptomatic pediatric malaria patients against microscopy of Giemsa-stained blood films and to evaluate the effectiveness of SD Bioline malaria AgPf(HRP-2/pLDH) in monitoring the efficacy of ACT (artesunate amodiaquine) among pediatric patients in Kinshasa, DRC where P. falciparum transmission is characterized as high [5] .
Methods

Study area, population and procedures
This study was conducted at Tembo Health Center in Kinshasa in DRC from October to December 2012. The health facility was chosen because of its relatively high number of pediatric patients in the 3 months preceding this study. This high number of pediatric patients was used as indicative of the availability of sufficient study participants. All pediatric patients who presented with symptoms of malaria during the study were invited to participate. After obtaining consent from patients' parents or guardians, demographic and clinical data were collected including previous anti-malarial drug intake. Blood samples (finger prick or venous blood) for thick and thin blood films and for the SD Bioline malaria AgPf(HRP-2/pLDH) RDT were collected from the patients on the day of recruitment (day 0). Blood slides were stained with Giemsa 3% for 30 minutes. The first slide readings were performed at the study site while the second readings were conducted at the National Biomedical Organisation (WHO) [7] . To monitor the persistence of HRP-2/pLDH in the blood, respondents were followed for 28 days from day 0.
Thus, besides day 0, blood samples for thick and thin blood films as well as for the SD Bioline malaria Pf (HRP-2/pLHD) RDT were collected on day 3, day 7, day 14, day 21 and day 28. The tests were performed following the same procedure as described above.
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Operational case definitions
Sensitivity of the RDT assay is defined herein as its ability to Positive predictive value (PV+) is the probability that when the test is reactive, the specimen actually contains malaria antigen. PV+ is calculated as TP/(TP + FP). Negative predictive value (PV-) is the probability that when a test is negative, a specimen does not have malaria antigen. PV-is calculated as TN/(FN+TN).
Data analysis
Data were entered into MS Excel (Redmond, WA, USA) independently by two people. The two datasets were then compared and discrepancies were corrected to create the final version that was analyzed using IBM SPSS Statistics version 20 (Chicago, IL, USA). The performance of SD Bioline malaria AgPf(HRP-2/pLDH) RDT was assessed by measuring its sensitivity, specificity, positive and negative predictive values against blood smear microscopy as the gold standard [8] .
The proportion of false positives among the children were estimated as a function of PfHRP-2/pLDH antigen present in <1,000 parasites/µl, 1001 -5,000 parasites/µl, 5,001 -50,000 parasites/µl and in > 50,000 parasites/µl on day 3, 7, 14, 21 and 28. In other words, this represented the percentage of participants who tested positive for AgPf(HRP-2/pLDH) RDT while having a negative blood smear test for a given parasite density level and day of follow up.
We compared groups using Fisher's exact test. The level of significance was set up at p < 0.05.
Ethical approval
This study was first approved by the DRC National Biomedical Research Institute's Research Committee. Written informed consent was sought from parents or guardians of the children who participated in this study. The parents or guardians were assured that the data would be kept confidential and used only for research purposes. Participants who tested positive for malaria were given standard malaria management as stipulated by the DRC National Malaria Control Program and WHO.
Results
Study participants
In total, 501 children were screened for P. falciparum in this study.
Their mean (standard deviation) age was 26.9 (5.8) months. The youngest was 3.4 months old while the oldest was 53.2 months old.
Two hundred and thirty six (47.1%) participants who were screened were females and 265 (52.9%) were males. Three hundred and thirty five (66.9%) participants tested negative for malaria while 166
(33.1%) tested positive for malaria infection. Parents/guardians of 103 children (out of the 166) gave consent to participate in the follow up part of the study, giving a response rate of 62.0%.
SD Bioline malaria AgPf(HRP-2/pLDH) performance
The frequency distribution of the study participants by parasite density level is presented in Table 1 whereby the parasitaemia bracket 5,001-50,000/μl had the highest percentage of children i.e.
12.8%. Results of the SD Bioline malaria AgPf(HRP-2/pLDH) RDT performance against blood smear microscopy as the gold standard are presented in Table 2 . SD Bioline malaria AgPf(HRP-2/pLDH) RDT exhibited high sensitivity, specificity, positive and negative predictive values. Table 3 presents the sensitivity of SD Bioline malaria AgPf(HRP-2/pLDH) RDT by level of P. falciparum parasitaemia. The sensitivity of SD Bioline malaria AgPf(HRP-2/pLDH) ranged from 85.1% to 100%. The RDT exhibited its lowest sensitivity when the parasitaemia was less than 10,000/μl.
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SD Bioline malaria AgPf(HRP-2/pLDH) performance during follow up days
One hundred and three patients who were positive for P. falciparum on day 0 and their parents or guardians consented to participate in this study were followed up till day 28. They were 48 females and 55 males. Their mean age (standard deviation) was 31.4 (7.4) months. The youngest was 6 months old and the oldest was 50 months. After treatment, on day 3 and day 7, all patients tested negative by blood smear microscopy. On day 14, two patients became positive by blood smear microscopy and two were lost to follow up. On day 21, four more patients became positive and six were lost to follow up. On day 28, eleven other patients became positive making a total of 17 patients who became positive. 
Discussion
The main finding of this study is that the performance of SD Bioline malaria AgPf(HRP-2/pLDH) RDT among pediatric patients with symptomatic malaria in Kinshasa, DRC was high. The test attributes for testing and monitoring the efficacy of ACT treatment among pediatric patients in the population studied were reasonably high.
The sensitivity and specificity of the test were found to be high. The corresponding positive and negative predictive values were also high indicating the high performance of this test.
Although the sensitivity of the test went a bit down to 85.1% among patients with parasite densities ≤ 1,000/μl, this study showed sensitivity of about 100% for parasite densities > 1,000/μl. Similar results are found in the literature [9, 10] . These results indicate that when using SD Bioline malaria AgPf(HRP-2/pLDH) RDT in this population, the probability of testing positive when one truly has malaria is more-or-less 100% which indicates high performance of this test in Kinshasa, DRC. Tables and figure   Table 1 : Frequency distribution of the study participants by parasite density level Table 2 : SD Bioline malaria AgPf(HRP-2/pLDH) performance against blood smear microscopy as the gold standard RDT = rapid diagnostic test, + = positive, -= negative, PV+ = positive predictive value; PV-= negative predictive value Sens = sensitivity, spec = specificity, NA = not applicable, + = positive and -= negative 
